Table 2.
Three-year study period and lifetime projections of YLD within core sample, disaggregated by the severity of HRQoL impairment at T0, and presented for the total cohort, and stratified by gender and HIV status
| Disability over the 3- year follow-up period | Projected lifetime disability (including 3-year post-treatment) | Disability weights | |||||||||
| N | Mean YLD | Total YLD | Burden | N | Mean YLD | Total YLD | Burden | During 3 years | After 3 years | ||
| All participants in core sample (n=299) | *Least severe 20% | 94 | 0.000 | 0.000 | 0% | 94 | 0.000 | 0.000 | 0% | 0.000 | 0.000 |
| – | 30 | 0.012 | 0.371 | 1% | 29 | 0.012 | 0.360 | 0% | 0.004 | 0.000 | |
| – | 55 | 0.041 | 2.238 | 8% | 57 | 0.042 | 2.419 | 1% | 0.014 | 0.000 | |
| – | 60 | 0.111 | 6.672 | 24% | 60 | 0.154 | 9.253 | 5% | 0.037 | 0.000 | |
| Most severe 20% | 60 | 0.315 | 18.890 | 67% | 59 | 3.062 | 180.629 | 94% | 0.105 | 0.083 | |
| All 3-year participants | 299 | 0.094 | 28.171 | 100% | 299 | 0.644 | 192.662 | 100% | 0.031 | 0.016 | |
| Men (n=198) | Least severe 20% | 70 | 0.000 | 0.000 | 0% | 38 | 0.000 | 0.000 | 0% | 0.000 | 0.000 |
| – | 11 | 0.009 | 0.102 | 1% | 10 | 0.009 | 0.092 | 0% | 0.003 | 0.000 | |
| – | 38 | 0.038 | 1.427 | 8% | 38 | 0.038 | 1.438 | 2% | 0.013 | 0.000 | |
| – | 41 | 0.107 | 4.390 | 25% | 40 | 0.134 | 5.365 | 6% | 0.036 | 0.000 | |
| Most severe 20% | 38 | 0.307 | 11.661 | 66% | 40 | 2.096 | 83.845 | 92% | 0.102 | 0.060 | |
| All men | 198 | 0.089 | 17.580 | 100% | 198 | 0.458 | 90.739 | 100% | 0.030 | 0.012 | |
| Women (n=101) | Least severe 20% | 24 | 0.000 | 0.000 | 0% | 24 | 0.000 | 0.000 | 0% | 0.000 | 0.000 |
| – | 19 | 0.015 | 0.286 | 3% | 19 | 0.015 | 0.286 | 0% | 0.005 | 0.000 | |
| – | 18 | 0.048 | 0.867 | 8% | 18 | 0.050 | 0.901 | 1% | 0.016 | 0.000 | |
| – | 21 | 0.139 | 2.912 | 27% | 20 | 0.224 | 4.483 | 4% | 0.046 | 0.001 | |
| Most severe 20% | 19 | 0.343 | 6.525 | 62% | 20 | 4.813 | 96.253 | 94% | 0.114 | 0.125 | |
| All women | 101 | 0.105 | 10.591 | 100% | 101 | 1.009 | 101.923 | 100% | 0.035 | 0.025 | |
| HIV-positive participants (n=179) | Least severe 20% | 57 | 0.000 | 0.000 | 0% | 57 | 0.000 | 0.000 | 0% | 0.000 | 0.000 |
| – | 19 | 0.013 | 0.246 | 2% | 19 | 0.013 | 0.246 | 0% | 0.004 | 0.000 | |
| – | 35 | 0.039 | 1.373 | 10% | 33 | 0.038 | 1.268 | 2% | 0.013 | 0.000 | |
| – | 32 | 0.090 | 2.876 | 22% | 34 | 0.108 | 3.663 | 5% | 0.030 | 0.000 | |
| Most severe 20% | 36 | 0.243 | 8.759 | 66% | 36 | 2.069 | 74.471 | 93% | 0.081 | 0.052 | |
| All HIV positive | 179 | 0.074 | 13.254 | 100% | 179 | 0.445 | 79.649 | 100% | 0.025 | 0.010 | |
| HIV-negative participants (n=119) | Least severe 20% | 37 | 0.000 | 0.000 | 0% | 37 | 0.000 | 0.000 | 0% | 3.333 | 0.000 |
| – | 11 | 0.011 | 0.125 | 1% | 10 | 0.011 | 0.115 | 0% | 8.000 | 0.000 | |
| – | 23 | 0.048 | 1.113 | 8% | 24 | 0.055 | 1.317 | 1% | 8.000 | 0.000 | |
| – | 24 | 0.161 | 3.852 | 26% | 24 | 0.269 | 6.451 | 6% | 8.000 | 0.002 | |
| Most severe 20% | 24 | 0.400 | 9.593 | 65% | 24 | 4.321 | 103.714 | 93% | 39.667 | 0.122 | |
| All HIV negative | 119 | 0.123 | 14.683 | 100% | 119 | 0.938 | 111.597 | 100% | 0.041 | 0.025 | |
Shaded cells show average DWs for each subgroup, appropriate for YLD calculations in an economic evaluation. They are calculated as the mean 3-yearYLD divided by three. For HIV status within gender, see online supplemental appendix table F3.
*Note least severe groupings larger due to number of participants measuring no impairment at T0. Further note, grouping by HIV status does not include one participant who declined testing.
HRQoL, health-related quality of life; YLD, years of life lost due to disability.